193 related articles for article (PubMed ID: 11774944)
1. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.
Lewis JD; Lichtenstein GR; Stein RB; Deren JJ; Judge TA; Fogt F; Furth EE; Demissie EJ; Hurd LB; Su CG; Keilbaugh SA; Lazar MA; Wu GD
Am J Gastroenterol; 2001 Dec; 96(12):3323-8. PubMed ID: 11774944
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
Mantzaris GJ; Archavlis E; Christoforidis P; Kourtessas D; Amberiadis P; Florakis N; Petraki K; Spiliadi C; Triantafyllou G
Am J Gastroenterol; 1997 Mar; 92(3):454-6. PubMed ID: 9068468
[TBL] [Abstract][Full Text] [Related]
3. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Folwaczny C; Wiebecke B; Loeschke K
Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
[TBL] [Abstract][Full Text] [Related]
4. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G
Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735
[TBL] [Abstract][Full Text] [Related]
6. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study.
Kono T; Nomura M; Kasai S; Kohgo Y
Am J Gastroenterol; 2001 Mar; 96(3):793-7. PubMed ID: 11280553
[TBL] [Abstract][Full Text] [Related]
7. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
8. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.
Sands BE; Sandborn WJ; Feagan B; Löfberg R; Hibi T; Wang T; Gustofson LM; Wong CJ; Vandervoort MK; Hanauer S;
Gastroenterology; 2008 Aug; 135(2):400-9. PubMed ID: 18602921
[TBL] [Abstract][Full Text] [Related]
10. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
11. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
[TBL] [Abstract][Full Text] [Related]
12. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
14. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.
Stremmel W; Merle U; Zahn A; Autschbach F; Hinz U; Ehehalt R
Gut; 2005 Jul; 54(7):966-71. PubMed ID: 15951544
[TBL] [Abstract][Full Text] [Related]
15. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan.
Hibi T; Sameshima Y; Sekiguchi Y; Hisatome Y; Maruyama F; Moriwaki K; Shima C; Saniabadi AR; Matsumoto T
Dig Liver Dis; 2009 Aug; 41(8):570-7. PubMed ID: 19211314
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis.
Langmead L; Feakins RM; Goldthorpe S; Holt H; Tsironi E; De Silva A; Jewell DP; Rampton DS
Aliment Pharmacol Ther; 2004 Apr; 19(7):739-47. PubMed ID: 15043514
[TBL] [Abstract][Full Text] [Related]
17. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis.
Kanke K; Nakano M; Hiraishi H; Terano A
Dig Liver Dis; 2004 Dec; 36(12):811-7. PubMed ID: 15646427
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
Schreiber S; Keshavarzian A; Isaacs KL; Schollenberger J; Guzman JP; Orlandi C; Hanauer SB
Gastroenterology; 2007 Jan; 132(1):76-86. PubMed ID: 17241861
[TBL] [Abstract][Full Text] [Related]
20. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
Sawada K; Kusugami K; Suzuki Y; Bamba T; Munakata A; Hibi T; Shimoyama T
Am J Gastroenterol; 2005 Jun; 100(6):1362-9. PubMed ID: 15929771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
